**6. Conclusion**

Immunotherapy-associated uveitis is an increasing occurrence that has become more apparent with the increased use of immunologic cancer treatments. Both ICI and BRAF/MEK therapies help improve survival in cancer patients by improving the patient's ability to attack cancer cells. Due to the positive effects these medications provide to metastatic and unresectable cancer patients, we hypothesize that more patients would continue to benefit from their use. With ongoing approvals and combinations of new medications, we may continue to foresee new information about ocular irAEs. Generally, most patients can be treated successfully with topical or systemic steroids without needing to hold or completely discontinue their cancer treatment. The way we treat and monitor these uveitis patients is based on limited literature, for which more controlled and standardized studies are needed to help have better treatment and monitoring algorithms. It remains unclear when to stop or discontinue cancer immunotherapies in patients with immunotherapy-associated uveitis. However, it is of utmost importance for oncologists, ophthalmologists, and all physicians involved in the care of cancer patients to be aware of the complications of these medications for prompt diagnosis and referral to improve patient care. Although relatively rare, the most crucial aspect of immunotherapy-associated uveitis is that it requires prompt recognition and treatment to avoid irreversible ocular damage. Any decision to hold or permanently discontinue these potentially lifesaving cancer medications should be thoroughly evaluated and discussed between the oncologists and ophthalmologists.
